The 8 most recent market catalysts affecting $EW, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Jul 24, 2026
Corporate Catalyst
Bullish
Impact 55
JP Morgan Maintains Overweight on Edwards Lifesciences, Raises Price Target to $105
JP Morgan's analyst Robbie Marcus maintained an 'Overweight' rating on Edwards Lifesciences and raised the price target from $100 to $105. This action signals continued confidence …
Jul 24, 2026
Corporate Catalyst
Bullish
Impact 85
Edwards Earnings Add Fuel To Bullish MedTech Thesis, Analyst Says
Edwards Lifesciences exceeded Wall Street's Q2 earnings and revenue estimates, reporting adjusted earnings of 78 cents per share against an estimated 74 cents, and revenue of $1.74…
Jul 24, 2026
Corporate Catalyst
Bullish
Impact 85
Edwards Lifesciences shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 sales guidance.
Edwards Lifesciences' strong earnings and optimistic long-term guidance are a significant positive catalyst for the company, indicating strong operational execution and market dema…
Jul 23, 2026
Corporate Catalyst
Bullish
Impact 92
Edwards Lifesciences shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 sales guidance.
Edwards Lifesciences' impressive Q2 earnings beat and raised long-term guidance are a major positive catalyst, directly impacting EW shares. This strong performance suggests robust…
Jul 23, 2026
Corporate Catalyst
Neutral
Impact 75
Edwards Lifesciences Sees Q3 Adj EPS $0.71-$0.77 vs $0.74 Est; Sees Sales $1.630B-$1.710B vs $1.689B Est
Edwards Lifesciences (EW) released its Q3 guidance, projecting adjusted EPS of $0.71-$0.77, which is largely in line with the analyst estimate of $0.74. However, the company's sale…
Jul 23, 2026
Corporate Catalyst
Bullish
Impact 92
Edwards Lifesciences Q2 Adj. EPS $0.78 Beats $0.74 Estimate, Sales $1.741B Beat $1.700B Estimate
Edwards Lifesciences announced Q2 adjusted EPS of $0.78, beating the consensus estimate of $0.74 by 5.41%, and sales of $1.741 billion, surpassing the $1.700 billion estimate by 2.…
Jul 15, 2026
Corporate Catalyst
Bullish
Impact 55
Mizuho Maintains Outperform on Edwards Lifesciences, Raises Price Target to $105
Mizuho analyst Anthony Petrone maintained an 'Outperform' rating on Edwards Lifesciences (EW) and raised the price target from $100 to $105. This action signals an analyst's increa…
Jul 13, 2026
Corporate Catalyst
Bullish
Impact 55
RBC Capital Maintains Outperform on Edwards Lifesciences, Raises Price Target to $110
RBC Capital analyst Shagun Singh maintained an Outperform rating on Edwards Lifesciences and raised the price target from $100 to $110. This action signals increased confidence fro…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.